Stent Tek Ltd.

Stent Tek Ltd. is a medical technology firm focused on enhancing vascular procedures, particularly in haemodialysis and arterial bypass interventions, through innovative solutions that improve patient safety and procedural efficacy. Founded in 2014, Stent Tek Ltd. is headquartered in London, UK, and specializes in advanced healthcare technology.

The company has completed a total of 4 funding deals, with the latest round in December 2021, raising GBP 8. 5 million from investors including BGF, Deepbridge Capital, and Parkwalk Advisors. The current company valuation stands at GBP 14. 712 million.

The founders, Robert Dickinson and Sorin Popa, have been instrumental in establishing the company and driving its growth. Pathfinder Medical specializes in advanced healthcare technology aimed at improving vascular procedures, particularly focusing on enhancing the safety and reliability of haemodialysis and arterial bypass interventions. Their core product offerings include innovative platforms that facilitate safe needle crossing and guidewire placement across blood vessels, addressing significant clinical needs in global markets. The technology is designed to cater to dialysis patients and those requiring surgical arteriovenous fistula (AVF) creations, addressing the unmet demands of a market valued at GBP 4.

2 billion annually. The company targets healthcare providers, including hospitals and specialty clinics, with its solutions being marketed primarily in Europe and select regions outside the United States. The overarching goal is to provide effective tools that enhance patient outcomes in vascular care. Pathfinder Medical generates revenue through direct sales of its proprietary medical technologies to healthcare institutions and providers involved in vascular treatments.

The transaction structure typically involves B2B interactions, where healthcare facilities procure these advanced tools to enhance patient care. Pricing plans are established based on the specific services and technologies utilized, ensuring that healthcare providers can access state-of-the-art solutions tailored to their needs. Notably, the company’s flagship products are integral to the operational workflows within dialysis centers and surgical units, facilitating critical procedures and improving patient outcomes. Revenue is derived from these direct transactions, with ongoing partnerships potentially enhancing service delivery and product adoption across their targeted markets.

In December 2021, Stent Tek Ltd. raised GBP 8. 5 million in venture funding to support additional pre-clinical work, complete a pivotal trial in patients, and secure regulatory approval prior to commercialization in key medical markets globally. The company plans to expand its product offerings, enhancing its current technological solutions while targeting new geographical markets to establish a broader customer base by the end of 2023.